DHL Group acquires CRYOPDP to enhance pharma logistics

DHL Group has acquired CRYOPDP to enhance pharma logistics and aligns with its 2030 strategy to lead in life sciences and healthcare logistics, said Oscar de Bok, CEO, DHL Supply Chain. DHL and Cryoport announced partnership to strengthen global supply chain services for the life sciences and healthcare sectors. “The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialised Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies. This is in addition to increasing our footprint in the conventional pharma and life science healthcare segment. The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities,” he added.